title: Editorial: fenofibrate as second-line therapy in high risk PBC--more answers or more questions? Authors' reply.
authors: Toronto Centre for Liver Disease, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada. angelac.cheung@uhn.ca.
authors: A C
authors: AC
authors: Cheung
authors: Toronto Centre for Liver Disease, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.|Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
authors: M
authors: M
authors: Kowgier
authors: Toronto Centre for Liver Disease, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.|McLaughlin-Rotman Centre for Global Health, University of Toronto, Toronto, ON, Canada.
authors: J J
authors: JJ
authors: Feld
mesh_terms: D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy*; D008297:Male; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*
chemical_list: D014580:Ursodeoxycholic Acid; D011345:Fenofibrate